Protagonist Therapeutics Inc PTGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress
-
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
-
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
-
Protagonist Therapeutics Reports Granting of Inducement Awards
-
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
-
Johnson & Johnson Gets FDA Approval for Icotyde in Plaque Psoriasis — Update
-
Johnson & Johnson Gets FDA Approval for Icotyde in Plaque Psoriasis
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 64.31M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 157.05
- Price/Sales
- 86.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 131
- Website
- https://www.protagonist-inc.com
Valuation
|
Metric
|
PTGX
|
|---|---|
Price/Earnings (Normalized) | 157.05 |
Price/Book Value | 9.54 |
Price/Sales | 86.06 |
Price/Cash Flow | — |
Price/Earnings
PTGX
Financial Strength
|
Metric
|
PTGX
|
|---|---|
Quick Ratio | 17.51 |
Current Ratio | 17.76 |
Interest Coverage | — |
Quick Ratio
PTGX
Profitability
|
Metric
|
PTGX
|
|---|---|
Return on Assets (Normalized) | −9.68% |
Return on Equity (Normalized) | −10.43% |
Return on Invested Capital (Normalized) | −14.31% |
Return on Assets
PTGX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Gcfvjhld | Phtsx | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xdjqzpdx | Cgslkp | $67B | |||
| argenx SE ADR
ARGX
| Vwnhqvlv | Cssn | $55B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mtfplbfnm | Ywghbtc | $40B | |||
| Royalty Pharma PLC Class A
RPRX
| Kxsbcyhfb | Jdgmc | $25B | |||
| BioNTech SE ADR
BNTX
| Sdqfnkc | Nrfh | $22B | |||
| Incyte Corp
INCY
| Qsnczvvnf | Wtbt | $20B | |||
| Moderna Inc
MRNA
| Gmhwctq | Mqb | $19B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Ktbrdzqm | Dfr | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Vwdztynsy | Gggc | $13B |
United States